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Abstract
Background: Toluene diisocyanate (TDI) is a highly reactive compound used in the production of, e.g.,
polyurethane foams and paints. TDI is known to cause respiratory symptoms and diseases. Because TDI
causes symptoms in only a fraction of exposed workers, genetic factors may play a key role in disease
susceptibility.
Methods: Workers (N = 132) exposed to TDI and a non-exposed group (N = 114) were analyzed for
genotype (metabolising genes: CYP1A1*2A, CYP1A1*2B, GSTM1*O, GSTM3*B, GSTP1 I105V, GSTP1 A114V,
GSTT1*O, MPO -463, NAT1*3, *4, *10, *11, *14, *15, NAT2*5, *6, *7, SULT1A1 R213H; immune-related
genes: CCL5 -403, HLA-DQB1*05, TNF -308, TNF -863) and symptoms of the eyes, upper and lower airways
(based on structured interviews).
Results: For three polymorphisms: CYP1A1*2A, CYP1A1*2B, and TNF -308 there was a pattern consistent
with interaction between genotype and TDI exposure status for the majority of symptoms investigated,
although it did reach statistical significance only for some symptoms: among TDI-exposed workers, the
CYP1A1 variant carriers had increased risk (CYP1A1*2A and eye symptoms: variant carriers OR 2.0 95%
CI 0.68–6.1, p-value for interaction 0.048; CYP1A1*2B and wheeze: IV carriers OR = 12, 1.4–110, p-value
for interaction 0.057). TDI-exposed individuals with TNF-308 A were protected against the majority of
symptoms, but it did not reach statistical significance. In the non-exposed group, however, TNF -308 A
carriers showed higher risk of the majority of symptoms (eye symptoms: variant carriers OR = 2.8, 1.1–
7.1, p-value for interaction 0.12; dry cough OR = 2.2, 0.69–7.2, p-value for interaction 0.036). Individuals
with  SULT1A1  213H had reduced risk both in the exposed and non-exposed groups. Other
polymorphisms, showed associations to certain symptoms: among TDI-exposed,NAT1*10 carriers had a
higher risk of eye symptoms and CCL5 -403 AG+AA as well as HLA-DQB1 *05 carriers displayed increased
risk of symptoms of the lower airways. GSTM1, GSTM3 and GSTP1 only displayed effects on symptoms of
the lower airways in the non-exposed group.
Conclusion: Specific gene-TDI interactions for symptoms of the eyes and lower airways appear to exist.
The results suggest different mechanisms for TDI- and non-TDI-related symptoms of the eyes and lower
airways.
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Background
Exposure to diisocyanates is well known to cause asthma
and symptoms such as cough, wheezing, and dyspnoea
[1]. Moreover, exposure to diisocyanates also often causes
symptoms from the upper airways such as rhinitis and
conjunctival irritation [2]. In a recent study we have
shown that TDI exposure can affect risk of symptoms from
the eyes, nose bleed, and symptoms of the lower airways
(odds ratios between 1.8–3.7) [3].
Because diisocyanates cause asthma in only a minor frac-
tion of exposed workers, genetic factors probably modify
disease susceptibility [4]. The metabolism of TDI is not yet
understood, but there is evidence that several different
metabolic pathways are involved in its biotransformation.
Isocyanates may react with intracellular glutathione,
either directly or through catalysis by the glutathione
transferase (GST) system. In the group of GST enzymes
that were analyzed, GSTP1 and GSTM1 were found to be
the most efficient catalysts of glutathione conjugation of
several different isothiocyanates [5]. Moreover, GSTs are
involved in the protection against reactive oxygen, which
is a key component of inflammation.
Non-enzymatic hydrolysis converts isocyanates to their
corresponding amines. There is ample proof that aromatic
and heterocyclic amines are activated by oxidation of the
primary amine by cytochrome P450 enzymes to aryl
hydroxylamines. The most important oxygenase is
CYP1A2, but also CYP1A1 and CYP1B1 can activate a
range of arylamines to reactive intermediates [6]. Another
frequent step in arylamine metabolism is the generation
of acetoxy esters by N-acetyltransferases (NAT1 and
NAT2). NAT1 is more abundant in the lung as well as in
the eye, but low levels of NAT2 have also been reported in
these tissues [7,8]. An additional step in the biotransfor-
mation of many aromatic amines is sulfatation by
cytosolic sulfotransferases (SULTs). A peroxidase-cata-
lysed mechanism, possibly through myeloperoxidase
(MPO) in neutrophiles, to activate arylamines has been
suggested [9]. Proof for neutrophilic activation in occupa-
tional asthma has been reported [10]. Functional poly-
morphisms in such metabolic genes affecting the
metabolism of diisocyanates have been studied for their
impact on isocyanate-related symptoms [11-14].
There are also several immune-related genes of relevance
for the susceptibility to respiratory diseases. The chemok-
ine CCL5 (also labeled RANTES) is responsible for the
recruitment of inflammatory cells, such as eosinophils
and T-lymphocytes. The HLA class II molecules are
involved in the immune responses as they bind antigen-
derived peptides and present them to lymphocytes via the
T-cell receptor. Mapp et al. have shown overrepresenta-
tion of the DQB1*0503 allele among subjects with TDI-
induced asthma [15]. Tumor necrosis factor alfa (TNF) is
chronically expressed in TDI-induced asthma [16] and a
study in TNF receptor knockout mice has shown that
these animals fail to develop immunological effects from
TDI [17].
The objective of the present study was to investigate
whether the associations of TDI and symptoms of the eyes
and airways were modified by relevant functional poly-
morphisms in metabolizing enzymes and/or in proteins
involved in airway inflammation. Thus, a group of work-
ers exposed to isocyanates, mainly TDI, and a non-
exposed group, not exposed to any isocyanates, were ana-
lyzed for genotype and health effects.
Materials and methods
Plants and exposure
The study encompassed eleven plants in the southern part
of Sweden. These plants are described in detail in Sennbro
et al. [18]. Plants selected were those 13 which were
expected to have the highest TDI exposure according to an
earlier investigation (referred to in [18]) and where at
least three employees worked with polyurethane and/or
isocyanates; 11 plants where TDI or TDI-based poly-
urethane was used in the manufacturing process agreed to
participate: five moulding plants, two continuous foam-
ing plants, two flame lamination plants, and two plants
with low- or non-heating processes. In four of the five
moulding plants, MDI was also used in the manufacturing
process although the exposures in air were low or non-
detectable. Additionally, in one of these four plants iso-
phorone diisocyanate was utilized.
Subjects
There were in total 184 occupationally TDI-exposed work-
ers employed at the plants and 132 workers participated
in the study. Out of a total 198 employees from five dif-
ferent facilities in southern Sweden, a group consisting of
114 workers, not occupationally exposed to isocyanates or
performing any plastic or rubber work, was included as
well. The pre-requisites to be included in the study were
that participants had agreed to take part in the genetic
analysis and that they were present at work/at the work
shift when the medical examinations took place. The
main limiting factor for inclusion in the study has been
absence at work shift on the day that the medical exami-
nation took place.
The characteristics of exposed and non-exposed workers
are presented in Table 1.
The median age in the exposed group was 36 years (range
18–64), and in the non-exposed group 39 (18–61). The
non-exposed group has been described in more detail in
Sennbro et al. [19]; they did not handle any isocyanates,Environmental Health 2008, 7:15 http://www.ehjournal.net/content/7/1/15
Page 3 of 11
(page number not for citation purposes)
polyurethanes or other plastics. Moreover, they were not
involved in heating operations. This study was approved
by the Regional Ethics Committee at Lund University,
Sweden. Written informed consent was obtained from all
subjects.
Health examinations
The health examinations are described in detail in Littorin
et al. [3]. In the present study we have only focused on
symptoms which were shown by Littorin et al. [3] to be
significantly associated with TDI exposure. In short, a
physician compiled thorough medical and occupational
histories from questionnaires with interviews. Symptoms
during the last twelve months were recorded and i.a. the
following symptoms were registered: symptoms from the
eyes, symptoms from lower airways and nose bleed (Table
1). At least one of itching, running, or burning was
defined as symptoms of the eyes. Cough with mucus,
attacks of severe dry cough, attacks of at least one of dysp-
noea, wheezing, or chest tightness were defined as symp-
toms of the "lower airways" (dyspnoea, wheezing, or
chest tightness are in the following text labeled as "wheeze
etc."). The employees were physically examined during
workdays. Venous blood and urinary samples were col-
lected at work and stored at -20°C. Blood was analyzed
for genotypes, plasma and urine for biomarkers of isocy-
anates. Serum was screened for atopy by the Phadiatop
fluoroimmunoassay test [20], which was considered pos-
itive when at least one of 11 airborne allergens [dog, cat,
horse, timothy, birch, mugwort, mite (D. pteronyssinus,
Table 1: Characteristics of the study subjectsa.
Exposed workers Non-exposed workers
N% N %
Sexb** Male/Female 107/25 81/19 55/59 48/52
Smoker No+Former/Yes 77/52 60/40 71/42 63/37
Atopy Negative/Positive 94/37 72/28 82/31 73/27
SYMPTOMS
Eye symptomsb** No/Yes 71/57 55/45 89/25 78/22
Wheeze etc. No/Yes 88/41 68/32 90/24 79/21
Dry coughb** No/Yes 88/39 69/31 101/13 89/11
Cough with mucus No/Yes 84/44 66/34 87/27 76/24
Nose bleedb** No/Yes 96/28 78/23 107/7 94/6
GENOTYPES/PHENOTYPES
GSTM1 +/- 65/67 49/51 65/49 57/43
GSTT1 +/- 110/22 83/17 97/17 85/15
GSTM3 AA/AB/BB 94/36/2 71/27/2 78/31/5 68/27/4
GSTP1*105 II/IV/VV 68/51/13 52/39/10 57/46/11 50/40/10
GSTP1*114 AA/AV 114/18 86/14 103/11 90/10
GSTP1*105 +114 A/B/C 68/46/18 51/35/14 57/46/11 50/40/10
NAT1 phenotype S/IM/R 3/88/41 2/67/31 3/76/35 3/67/30
NAT2 phenotype S/IM/R 89/33/10 67/25/8 73/38/3 64/33/3
MPOb** GG/GA/AA 97/29/6 73/22/5 74/40/0 65/35/0
SULT1A1 GG/GA/AA 43/77/12 33/58/9 46/54/14 40/47/12
CYP1A1*2A A/B/C 116/14/2 88/11/2 97/16/1 85/14/1
CYP1A1*2B AA/AG/GG 126/5/1 95/4/1 107/7/0 94/6/0
TNF-308 GG/GA/AA 83/35/4 68/29/3 69/35/5 63/32/5
TNF-863 CC/CA/AA 93/28/6 73/22/5 78/32/2 70/29/2
CCL5 GG/GA/AA 84/38/5 66/30/4 72/36/4 64/32/4
HLA-DQB1*05 -/+ 88/39 69/31 87/25 78/22
HLA-DQB1*0501b* -/+ 98/29 77/23 98/14 88/12
HLA-DQB1*0502 -/+ 118/9 93/7 105/7 94/6
HLA-DQB1*0503 -/+ 125/2 98/2 108/4 96/4
HLA-DQB1*0504 -/+ 126/1 99/1 112/0 100/0
aData was incomplete for some individuals studied, but these study subjects were included in the analyses when possible. Due to variations in 
success rate of the genotype analyses, the number of analyzed individuals differs to some extent between the different polymorphisms. Moreover, 
all 246 individuals approved analysis of metabolizing genes, whereas 239 individuals approved analysis of immune-related genes.
bStatistically significant differences between exposed and non-exposed workers.
*p < 0.05, **p < 0.01.Environmental Health 2008, 7:15 http://www.ehjournal.net/content/7/1/15
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D. farinae), mould (Cladosporium), olive, Parietaria] pro-
vided a response. The test has a sensitivity and a specificity
of 95% (according to the company supplying the test).
Exposure assessment methods
Personal exposure was monitored by air measurements
and by analysis of biomarkers of exposure in urine and
plasma [21,22]. The exposed subjects were exposed to
measurable concentrations of airborne TDI (the personal
8-hour time-weighted average levels were for 2,4 TDI:
median 0.32 ppb, range below limit of detection (LOD)-
2.6 ppb; 2,6-TDI: median 0.27 ppb [0.01–3.6]). The
exposed workers had detectable levels of biomarkers in
urine (2,4-TDA: median 23 nmol/L [LOD-620]; 2,6-TDA:
median 30 nmol/L [LOD-350 nmol/L]) and in plasma
(2,4-TDA: median 38 nmol/L [LOD-250]; 2,6-TDA:
median 35 nmol/L [LOD-510]); for both analyses LOD =
0.41 nmol/L. No air monitoring was performed in the
group of non-exposed workers. However, as much as 15%
of them had detectable, but very low, concentrations of
biomarkers in urine (2,4-TDA median LOD nmol/L
[LOD-3.3]; 2,6-TDA median LOD nmol/L [LOD-1.6]) or
plasma (2,4-TDA median LOD nmol/L [LOD -0.82]; 2,6-
TDA median LOD nmol/L [LOD-0.82]) respectively,
reflecting background exposure [19].
Genotyping
DNA for genotyping was prepared from white blood cells.
Due to variations in success rate of the genotype analyses,
the number of analyzed individuals differs to some extent
between the different polymorphisms. Moreover, all 246
individuals approved analysis of metabolizing genes,
whereas 239 individuals approved analysis of immune-
related genes.
Two closely linked single nucleotide polymorphisms
(SNPs) in the CYP1A1 gene were analyzed by PCR, as pre-
viously described [23]. The MspI restriction fragment
length polymorphism in the 3'end of CYP1A1 (found on
the CYP1A1*2A allele) is due to a C>T base substitution
264 base pairs downstream the poly(A) signal. The
CYP1A1*2B allele (A>G) contains an additional replace-
ment of isoleucine by valine at residue 462 in the heme
binding region of the enzyme.
Genotyping for the GSTM1 and GSTT1 null, and GSTP1
I105V (A>G) polymorphisms was performed as previ-
ously described [23]. The GSTP1 114 Ala (A) to Val (V)
substitution was analyzed by PCR and Dynamic Allele
Specific Hybridization (DASH) [24], using 5'-biotin-
AGTAGGATGATACATGGTGGTG as the forward and 5'-
GCAGTGCCTTCACATAGTCATC as the reverse PCR
primer, and 5'-CCTTGCCCGCCTCCTGCC and 5'-CCTT-
GCCCACCTCCTGCC as specific probes for the C (Ala)
and T (Val) alleles, respectively. When combining the gen-
otypes at both positions three groups were formed; A:
II+AA at position 105 and 114, respectively; B: IV+AA or
VV+AA; and C: IV+AV or VV+AV. The 3 bp deletion
(intron 6) of GSTM3 was analyzed by PCR/RFLP using the
restriction enzyme MnlI according to Inskip et al [25].
Five different SNPs in the NAT1 gene, 559 C>T, 560 G>A,
640 T>G, 1088 T>A and 1095 C>A, were analyzed to
determine the alleles *3 (1095 C>A), *4 (wild type), *10
(1088 T>A and 1095 C>A), *11 (640 T>G), *14 (560
G>A) and *15 (559 C>T), essentially as described by Deitz
et al [26]. However, the 560 SNP was analyzed by allele-
specific PCR using 5'-GTTAATTTCTGGGAAGGATCA as
the forward primer, and 5'-GAGTAAAGGAGTAGATTTTC
and 5'-GAGTAAAGGAGTAGATTTTT, as reverse primers,
to differentiate the G and A alleles. Individuals
homozygous or heterozygous for the NAT1*10 allele and
not carrying the *14 or *15 alleles were considered to
have the rapid acetylator phenotype (R). Individuals
homozygous for NAT1*3, *4 or *11 alleles were consid-
ered to have the intermediate phenotype (IM). The slow
acetylator alleles NAT1*14 and *15 were rare in the study
population: there were two individuals carrying *10*14
and *10*15 and four individuals carrying *4*14 and all
were considered as slow acetylators (S). NAT2 polymor-
phisms (341 T>C, 590 G>A, and 857 G>A) were analyzed
as previously described [27]. The NAT2 phenotype was
deduced from the genotype and subjects were classified as
slow (S = carriers of two mutations), intermediate (IM =
carriers of one mutation) or rapid (R = carriers of wild type
alleles only) acetylators.
For the MPO  G-463A polymorphism, a PCR/RLFP
method with AciI was used [28]. The SULT1A1, Arg213His
(R213H) was analyzed by PCR/RLFP using the restriction
enzyme Bsp143II to distinguish the G and A alleles accord-
ing to Engelke et al [29].
Analysis of CCL5 -403G/A was performed with a Taqman-
based assay (ABI PRISM 7000 instrument, according to a
standard protocol (Applied Biosystems)), forward (5'-
CACTTTATAAATAACATCCTTCCATGGAT) and reverse
primers (5'-TCAAAGTTCCTGCTTATTCATTACAGA),
MGB-probes (5'FAM-AGGGAAAGGAGGTAAGA for the
G-allele, and 5'VIC-AGGGAAAGGAGATAAG for the less
common A-allele), as well as 20 ng of template. The two
polymorphisms in TNF (-308 G/A and -863 C/A) were
analyzed with matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry (Seque-
nom™, San Diego, CA, USA) at the SWEGENE Resource
Center for Profiling Polygenic Disease, Lund University,
Malmö.  HLA-DQB1*05-genotype was assessed with
sequence-specific primers and amplification control
primers as previously reported [30].Environmental Health 2008, 7:15 http://www.ehjournal.net/content/7/1/15
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In all types of genetic assays, positive controls for each
genotype as well as a negative control (no template) were
included. Furthermore, for all assays at least 5% of the
samples were reanalyzed and the agreement between
these analyses was always 100%.
Statistical methods
The Hardy Weinberg equilibrium, which is the principle
for the relation between frequencies of alleles and the gen-
otype of a population was here used for indication of gen-
otyping errors and was tested for all genes with the Chi-
square test. The difference in characteristics for the study
subjects was evaluated with non-parametric tests (Mann-
Whitney or Kruskal Wallis). The genetic influence on the
symptoms was evaluated by comparing different geno-
types among exposed and non-exposed separately in
logistic regression analysis. In a further analysis, interac-
tion between genotype and exposure status (exposed/
non-exposed) was evaluated using logistic regression with
an interaction term (genotype)*(exposure). Effects were
estimated using odd ratios (ORs) together with 95% con-
fidence intervals (CIs). Statistical significance refers to P <
0.05 (two-tailed) or, equivalently, to 95% CI for an OR
that excludes 1.0. Unadjusted as well as adjusted analyses
were performed. Based on the general knowledge of
effects on symptoms of the airways and the eyes, we
adjusted for age, sex, smoking (nonsmoker + former
smoker vs. smoker), and atopy. Due to missing informa-
tion, 112 non-exposed and 128 exposed workers could be
included in the adjusted analysis compared to 114 non-
exposed and 132 exposed workers in the unadjusted anal-
yses. The genotypes of GSTM1, GSTT1, NAT1 and NAT2
were dichotomized according to the inferred phenotype:
present vs. null for GSTM1 and GSTT1, slow+intermediate
vs rapid for NAT1 or intermediate+rapid vs slow, and slow
vs. rapid+intermediate acetylation for NAT2. The main
effects of the remaining genes were first assessed sepa-
rately for each genotype; genotypes were subsequently
grouped based on prior biological knowledge of the allele
function or the frequency distribution in our material. For
analysis of gene-gene interactions, the analysis was lim-
ited to genotypes that were significantly associated with
symptoms in the single gene analysis. For example for
symptoms of the eyes, the combinations of NAT1 (catego-
rized as IM+S/R)+SULT1A1  (GG/AG+AA),  NAT1+TNF-
308 (GG/AG+AA), and SULT1A1+TNF-308 were evalu-
ated. All gene-gene combination analyses were adjusted
for sex, age, atopy and smoking.
The data were analysed for patterns of associations
between genetic markers and different symptoms and
such patterns were presented, although some effect esti-
mates/interaction terms did not reach statistical signifi-
cance. For genetic markers with no obvious pattern of
associations, only those resulting in significant effect esti-
mates/interaction terms were presented.
Results
There were statistically significant differences for sex (p-
value < 0.001), genotype distributions for MPO  (p =
0.008) and HLADQB1*0501 (p = 0.038) between
exposed and non-exposed groups (Table 1). Also there
were statistically significant or near significant differences
in prevalence of symptoms between the two groups
(symptoms of the eyes p < 0.001; wheezing p = 0.060; dry
cough p < 0.001; cough with mucus p = 0.069; and nose
bleed p < 0.001), which has been reported elsewhere [3].
All genes were found to be in Hardy Weinberg equilib-
rium in the entire study population. This was also true
when the subjects were divided into exposed and non-
exposed groups, except for SULT1A1, which among
exposed workers displayed more variant heterozygotes
than expected.
In Table 2, all results that demonstrated statistical signifi-
cance with respect to genotype-associated risk in either
exposure-strata, or interaction between genotype and
exposure status, are presented. For the majority of analy-
ses, the unadjusted results were very similar to the
adjusted. In the cases where the statistical significance dif-
fered, the unadjusted results are presented in the text
below. For the other genotypes, no statistically significant
associations were found.
For three polymorphisms: CYP1A1*2A, CYP1A1*2B, and
TNF -308 there was a pattern consistent with interaction
between genotype and exposure status for the majority of
symptoms investigated (Fig 1a–c). Among TDI-exposed
subjects, the carriers of the CYP1A1*2A variant (crude:
exposed workers OR = 1.9, 95% CI 0.62–5.8; non-
exposed workers OR = 0.18, 95% 0.021–1.5; interaction p
= 0.048 for symptoms of the eyes) and carriers of the
CYP1A1*2B variant, had an increased risk for symptoms
as compared to the non-exposed subjects. For TNF-308,
the variant A allele was associated with a higher risk of
symptoms among the non-exposed group, whereas the
opposite was found to be true for exposed subjects.
Among exposed subjects, the A variant allele was found to
protect particularly against wheeze etc., but also against
dry cough and cough with mucus (Fig 1c, wheeze etc.:
crude OR = 0.54, 95% CI 0.22–1.3, interaction p = 0.130).
For SULT1A1  R213H, there was no genotype exposure
interaction, but the AG+AA carriers had reduced risk as
compared to GG, both among exposed and non-exposed
subjects (Fig 1d).
For other polymorphisms, associations were restricted to
certain symptoms (Table 2). The rapid genotype of NAT1
was associated with a higher risk of symptoms of the eyesEnvironmental Health 2008, 7:15 http://www.ehjournal.net/content/7/1/15
Page 6 of 11
(page number not for citation purposes)
Table 2: Symptoms of the eyes and airways comparing different genotypes among TDI-exposed and non-exposed workers.a
Geno-type Symptoms
Yes (N) No (N) ORb 95% CI Pc*
EYES
Exposed NAT1 IM+S 33 53 1.0 - 0.067
R2 3 1 7 2.2 1.0–4.9
Unexposed NAT1 IM+S 19 60 1.0 -
R 6 27 0.63 0.22–1.9
Exposed SULT1A1 R213H GG 27 14 1.0 - 0.19
AG+AA 29 56 0.22 0.096–0.52
Unexposed SULT1A1 R213H GG 13 31 1.0
AG+AA 12 56 0.56 0.22–1.4
Exposed TNF-308 GG 36 44 1.0 - 0.11
GA+AA 17 19 1.0 0.47–2.4
Unexposed TNF-308 GG 11 57 1.0 -
GA+AA 14 25 2.6 1.0–7.0
WHEEZE
Exposed CYP1A1*2B I/I 34 87 1.0 - 0.061
I/V 5 1 14 1.5–130
Unexposed CYP1A1*2B I/I 23 82 1.0 -
I/V 1 6 0.83 0.090–7.7
Exposed SULT1A1 R213H GG 17 25 1.0 - 0.58
AG+AA 22 63 0.52 0.22–1.2
Unexposed SULT1A1 R213H GG 14 30 1.0 -
AG+AA 10 58 0.38 0.15–0.99
Exposed CCL5 -403 GG 19 64 1.0 - 0.42
AG+AA 20 21 3.1 1.3–7.1
Unexposed CCL5 -403 GG 13 58 1.0 -
AG+AA 10 29 1.8 0.68–5.0
Exposed TNF-308 GG 29 52 1.0 - 0.043
GA+AA 7 30 0.37 0.14–0.99
Unexposed TNF-308 GG 13 55 1.0 -
GA+AA 10 29 1.3 0.46–3.4
DRY COUGH
Exposed HLADQB1*05 Absent 20 62 1.0 - 0.047
Present 18 20 2.7 1.2–6.3
Unexposed HLADQB1*05 Absent 12 74 1.0 -
Present 1 23 0.27 0.031–2.2
Exposed TNF-308 GG 30 50 1.0 - 0.023
GA+AA 7 28 0.43 0.17–1.1
Unexposed TNF-308 GG 6 62 1.0 -
GA+AA 7 32 2.2 0.66–7.3
COUGH WITH MUCUS
Exposed GSTM1 Present 19 45 1.0 - 0.13
Absent 24 39 1.4 0.66–3.0
Unexposed GSTM1 Present 8 55 1.0 -
Absent 18 31 3.5 1.3–9.4
Exposed GSTM3 AA 29 61 1.0 - 0.028
AB+BB 14 23 1.2 0.52–2.7
Unexposed GSTM3 AA 23 53 1.0 -
AB+BB 3 33 0.22 0.059–0.81
Exposed GSTP1*105 I/I 26 41 1.0 - 0.019
I/V+V/V 17 43 0.66 0.32–1.4
Unexposed GSTP1*105 I/I 8 48 1.0 -
I/V+V/V 18 38 3.0 1.1–8.0
Exposed CCL5 -403 GG 22 59 1.0 - 0.079
AG+AA 21 20 2.9 1.3–6.5
Unexposed CCL5 -403 GG 17 54 1.0 -
AG+AA 8 31 0.86 0.32–2.3
NOSE BLEED
Exposed MPO GG 25 65 1.0 - 0.018
AG+AA 3 30 0.21 0.056–0.94
Unexposed MPO GG 3 70 1.0 -
AG+AA 4 35 2.9 0.58–14
a Adjusted effect estimates (for sex, age, atopy, and smoking) are presented as odds ratios (OR) and 95% confidence intervals. Statistically significant 
results are presented in bold.
bAll results that reached statistical significance with respect to genotype-associated risk in either exposure-strata, or in the analysis of interaction 
between genotype and exposure status, are presented.
cAnalysis of interaction between exposure and genotype was performed in a separate model using logistic regression with interaction term. P-
values regarding interaction between exposure and genotype are indicated by P*.Environmental Health 2008, 7:15 http://www.ehjournal.net/content/7/1/15
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among exposed and interaction was indicated but not sta-
tistically significant. CCL5 AG+AA carriers had up to three
times higher risk of wheeze etc. and cough with mucus
among exposed workers. Carrying HLA-DQB1*05 was
associated with an increased risk of dry cough among
exposed subjects, and interaction was statistically signifi-
cant. After subtyping for different HLA-DQ05 alleles, it
was found that HLA-DQB1*0502 carriers, but not *0501,
had an elevated risk of dry cough (*0502 OR = 4.9, 95%
CI 1.1–21) among exposed workers. There were too few
individuals with DQB1*0503 or *0504 for any associa-
tion analysis.
Individuals with GSTM3  AB+BB were protected from
cough with mucus among non-exposed subjects, with sta-
tistical significance for interaction. In the non-exposed
group,GSTM1 null as well as GSTP1*105I/V+V/V individ-
uals displayed significantly higher risk of cough with
mucus. For GSTP1, evidence of genotype-exposure inter-
action was found as well. Among exposed subjects, TNF-
863 CA+AA carriers had higher risk of cough with mucus
than CC (unadjusted analysis OR = 2.5, 95% CI 1.1–5.6;
adjusted analysis OR = 2.1 95% CI 0.91–5.0). Variant
allele carriers of MPO were protected against nose bleed
among exposed workers.
The gene-gene combinations analysis resulted in statisti-
cally significant associations between gene-gene combina-
tions and symptoms. However, the results did not differ
much from the results in the single gene analysis: e.g. for
the combination NAT1+SULT1A1 and symptoms of the
eyes, carriers of NAT1 IM+S and SULT1A1 AG+AA had an
OR = 0.19 95% CI 0.066–0.53; for the combination of
TNF-308 and SULT1A1 and wheeze etc., carriers of TNF-
308 AG+AA and SULT1A1 AG+AA displayed an OR = 0.27
95% CI 0.081–0.91. There was no strong evidence for
interaction apart from the combination of GSTM1 and
GSTP1 for cough with mucus among non-exposed work-
ers, where carriers of GSTM1 null and GSTP1*105 Val-
displayed OR = 22, 95% CI 2.5–200, compared to GSTM1
present and GSTP1*105 Ile/Ile.
Discussion
Gene-exposure interaction was observed for symptoms of
the eyes and lower airways, whereas there were no strong
indications of interaction for nose bleed. The CYP1A1
genotypes appeared to modify the effect of TDI. Similar
pattern for the MspI (*2A) variant as the Val (*2B) variant
was found, which probably is due to linkage between
these two polymorphisms [31]. However, the effect was
strongest for *2B, possibly reflecting the higher biological
relevance of this polymorphism. The difference between
the wild type Ile and the Val variant appears to depend on
the substrate: when the enzyme contained Val, ethoxyre-
sorufin exhibited a mildly elevated activity, and estrogen
exhibited a substantially elevated activity. No such effects
were observed for benzo(a)pyrene [32,33]. There are no
indications of effect of the MspI variant alone on the
a-d. Symptoms comparing different genotypes among TDI-exposed workers (exp) and non-exposed subjects (ref) Figure 1
a-d. Symptoms comparing different genotypes among TDI-exposed workers (exp) and non-exposed subjects 
(ref). Effect estimates are presented as crude odds ratios. Reference/variant genotypes are CYP1A1*2A A/B+C, CYP1A1*2B II/
IV, TNF-308 GG/GA+AA and SULT1A1 R213H GG/GA+AA. A 95% confidence interval is indicated. Values above the Y-axis are 
indicated with Arabic numbers. Significant values are displayed in Table 2.Environmental Health 2008, 7:15 http://www.ehjournal.net/content/7/1/15
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CYP1A1 activity [34]. The role of CYP1A1 for TDI-related
effects of the eyes and airways is at present largely
unknown. In a murine model of TDI asthma, challenging
with TDI resulted in an increased expression of CYP1A1 in
the lung [35]. However, the role of CYP1A1 for TDI-
asthma was unclear, since TDI seemed to partly inhibit the
activity of CYP1A1.
Elevated levels of TNF are frequently observed in bron-
choalveolar fluid of asthmatic subjects [36]. The -308G/A
variant has been shown to be associated with elevated
plasma TNF levels and with higher amounts of TNF upon
stimulation [37]. The -863C/A variant is associated with
reduced circulating levels of TNF [38]. In our study an
increased risk of symptoms was indicated for the variant
allele among the non-exposed group, which is in line with
what has been reported in other studies for TNF -308 and
non-occupational asthma [39]. However, we found that
among the exposed subjects, the variant allele of TNF -308
was associated with reduced risk among the exposed
whereas the variant of -863 was associated with increased
risk. Thus, our results indicate that genotypes associated
with low TNF circulating levels (-308 G and -863 A) may
be linked to symptoms in the TDI-exposed. The impact of
TNF polymorphism (-308) on TDI-asthma has been ana-
lyzed in a recent study by Beghé et al [40], but no associa-
tions were found in that study.
In SULT1A1, the variant allele of R213H (G/A), carries in
vitro only 10–25% of the activity of the more common
allele [41,42]. In our study, SULT1A1 showed significant
effect on symptoms from the eyes and on wheezing, and
a similar non-significant pattern was observed for all
symptoms analyzed. With regards to eye symptoms,
homozygotes for the more common allele G had up to
three times higher risk than individuals heterozygous or
homozygous for the low-activity A allele. However, the
data did not suggest a gene-exposure interaction due to
the fact that a protective effect was seen for exposed as well
as for referents.
Higher NAT1 and NAT2 activity could hypothetically con-
tribute to the formation of reactive damaging metabolites,
by O-acetylation, in the eyes and airways. Hence, the rapid
NAT1 and NAT2 genotypes could increase an individual's
risk for TDI-associated symptoms. Gene-TDI interaction
was suggested for NAT1 only for eye symptoms, where the
rapid genotype showed approximately two times higher
risk for symptoms among exposed workers. For NAT2
rapid acetylators, an increased risk was suggested for this
symptom as well (OR = 2.17, 95%CI 0.99–4.79, p =
0.054). For the lower airways, an association between
NAT1 slow genotype and increased risk for dry cough was
found (data not shown), but it was only among non-
exposed and there were no symptomatic exposed individ-
uals with slow genotype, making it very difficult to evalu-
ate the effect of this genotype. Thus, in contrast to
Wikman and colleagues (14), we did not find any reliable
associations with neither NAT1 nor NAT2 with the symp-
toms of the lower airways. The difference between the
studies on isocyanate-exposed workers could be due to
differences in selection of study subjects: in contrast to the
study by Wikman et al., this is a cross-sectional study and
the selection criterion was exposure and not disease.
Moreover, we studied predominantly TDI-exposed indi-
viduals and did not include study subjects with a mixed
diisocyanate exposure. Furthermore, in contrast to Wik-
man, we did not select asthma cases but rather analyzed
symptoms which may be early indicators of asthma-
related changes.
The -403G/A variant of CCL5 results in a new consensus
element for the GATA transcription factor family [43],
which suggests a role in the regulation of gene expression.
In the present study, the CCL5 genotype appeared to have
an effect on the risk for TDI-associated airway symptoms
such as wheeze etc. and cough with mucus: the variant
allele was associated with approximately three times
higher risk among exposed, suggesting a CCL5-TDI inter-
action. An association for CCL5 in TDI-associated airway
symptoms is also suggested from a recent study showing
increased expression of CCL5 in vitro in bronchial epithe-
lial cells when stimulated with TDI [44].
There was also evidence for association of HLA-DQB1*05,
in particular the *0502 allele, and isocyanate-related
symptoms of the lower airways. Compared to the *0501
allele, the *0502 has an exchange of a valine to a serine at
amino acid position 57 in the beta chain of HLA class II
molecules. Mapp et al. [15] have found an increased risk
of asthma for *0503 carriers (in *0503, valine is substi-
tuted with aspartic acid at position 57), which we were
unable to analyze, due to low number of study subjects
carrying this allele. In contrast to Mapp, we did not find a
protective effect for carriers of DQB1*0501 [15].
Glutathione S-transferases showed some effect on symp-
toms of the lower airways, in particular on cough with
mucus. However, the effect was not observed among the
exposed workers, but rather among the non-exposed sub-
jects. One possibility is that these symptoms are caused by
different mechanisms among exposed and non-exposed
individuals, i.e. GSTs are not involved in TDI-related air-
way obstruction. Piirilä and co-workers [12], found an
increased risk of diisocyanate-asthma among GSTM1*O
subjects. We found only a non-significant higher risk of
cough with mucus among the exposed subjects, and the
strongest effect was found among non-exposed subjects.
The differences in study design as discussed above for
NAT1 and NAT2 could also explain differences in resultsEnvironmental Health 2008, 7:15 http://www.ehjournal.net/content/7/1/15
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for GSTM1 compared to Piirilä et al., since both Wikman's
and Piirilä's reports are based on the same study popula-
tion. Other studies have reported higher risk of non-occu-
pational asthma for GSTM1*O subjects [45,46]. Piirilä
also studied GSTM3 in relation to diisocyanate-asthma
and found later reactions in the bronchial provocation
test among GSTM3*AA individuals. We also found that
GSTM3 was associated with airway symptom: there was a
protective effect of GSTM3*B on cough with mucus. How-
ever, this was only evident among the non-exposed indi-
viduals. For GSTP1, the exposed I/V+V/V displayed a
tendency towards a protective effect, which is in line with
the study by Mapp et al. (13) on TDI-asthma and GSTP1.
On the other hand, GSTP1  I/V+V/V subjects had an
increased risk of cough with mucus among the non-
exposed subjects.
Gene-gene interactions are of relevance to study, consider-
ing the complex metabolism of isocyanates as well as
responses of the immune system. However, since the
results differed for most polymorphisms for exposed and
non-exposed, we had to analyse the gene-gene interac-
tions in each group. The gene-gene combination analysis
did not indicate any evidence for departure from an addi-
tive effect. The exception was the results from the combi-
nation of GSTM1  and  GSTP1  for cough with mucus
among non-exposed workers. Nevertheless, there may still
be significant gene-gene interactions present for the symp-
toms analysed, however, for detection of such effects a
larger study population had been required.
The low prevalence of certain risk genotypes are reflected
in the large confidence interval for ORs obtained. Thus,
the data should at this point be cautiously interpreted and
new studies are needed for replication of the results.
Another aspect to consider is the issue of multiple interfer-
ences. We examined fifteen polymorphic loci, and five
symptoms for both exposed and non-exposed workers
which might result in a large number of false positives.
Nevertheless, no correction for multiple testing has been
performed. Adjustments such as the Bonferroni correction
are not applicable as they cannot take linkage between
polymorphisms into account, which occurs among some
genes investigated in our study. We do not stress individ-
ual significant findings, but rather believe that consistent
association patterns between genotypes and symptoms
indicate true findings.
By studying TDI-exposed as well as non-exposed individ-
uals, specific gene-TDI interactions were indicated for
symptoms of the eyes and lower airways. The finding that
certain genotypes modified the effect of symptoms arising
in different tissues suggests that these symptoms are asso-
ciated with each other and have common mechanisms.
We did not expect to find individuals diagnosed with
asthma among the exposed workers, since asthmatics
should not be employed in isocyanate workplaces in Swe-
den today, and if workers acquire asthmatic symptoms
after employment, they should be transferred to non-
exposed jobs. Surprisingly, increased risks of severe symp-
toms of the airways, e.g., wheeze and/or chest tightness,
which are associated with asthma (46), were recorded in
the present study. Thus, bearing in mind that our study is
a cross-sectional one, with potential for a healthy-worker-
selection, our findings may be an underestimation of the
true risk. Furthermore, gene-exposure interactions appear
to be present in early signs of health effects.
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